AWM
RGLS

Altus Wealth Management’s Regulus Therapeutics RGLS Stock Holding History

Altus Wealth Management’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,381
Closed -$19K – 36
2020
Q4 		$19K Buy
+1,381
New +$10.1K 0.01% 33

Other funds holding RGLS

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
ACM
Asymmetry Capital Management San Francisco, California $188M AUM 44.72% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Altus Wealth Management's RGLS Position: Q1 2021 in Review

Altus Wealth Management sold out of Regulus Therapeutics (RGLS) in Q1 2021, closing a stake of 1,381 shares — an estimated $19K sold.

Altus Wealth Management first reported a position in RGLS in Q4 2020 and held it in 1 quarter. The position peaked at $19K in Q4 2020. 44 funds tracked by Wall St. Rank hold RGLS as of Q1 2021.

  • Altus Wealth Management reported no remaining Regulus Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Altus Wealth Management sold 1,381 Regulus Therapeutics shares in Q1 2021, an estimated $19K.
  • Altus Wealth Management first reported a position in Regulus Therapeutics in Q4 2020 and held it in 1 quarter.
  • Altus Wealth Management's Regulus Therapeutics position peaked at $19K in Q4 2020.
  • 44 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q1 2021.

Based on Altus Wealth Management's 13F filing for Q1 2021, filed 21 Apr 2021.